LataMed AI Corp. (OTC: LMEDD) announced today that its previously announced 5-for-1 forward stock split has become effective at the opening of trading following publication of the corporate action on the FINRA Daily List dated July 14, 2026. The move is intended to consolidate the company's outstanding shares, which may improve the stock's liquidity and marketability as the development-stage digital health firm pursues commercialization of its artificial intelligence platforms.
In connection with the forward stock split, the Company's common stock will begin trading today under the temporary trading symbol LMEDD. The temporary "D" designation is a standard FINRA identifier used in connection with certain corporate actions and is expected to remain in place for approximately twenty business days, after which the trading symbol is expected to revert to LMED. The forward stock split has also been implemented in conjunction with the Company's mandatory share exchange and new CUSIP number, 21116R404. In connection with the corporate action, the Company's prior CUSIP number, 21116R305, is being suspended effective upon market effectiveness of the forward stock split.
The Company wishes to remind shareholders that those holding shares through brokerage accounts or in electronic book-entry form generally are not required to take any action. Brokerage firms, custodians, and other market participants are expected to process the corporate action automatically through the normal securities settlement process. Shareholders holding physical stock certificates are not required to immediately surrender their certificates. However, when physical certificates are presented to the Company's transfer agent for transfer, sale, or exchange, they will be processed in accordance with the mandatory exchange procedures then in effect and exchanged for the appropriate number of post-split shares under the new CUSIP.
Dr. Kevin Rodan Levy, Chief Executive Officer of LataMed AI Corp., stated: "Today's implementation of our forward stock split represents an important corporate milestone for LataMed AI. We appreciate the continued support of our shareholders and look forward to continuing the execution of our long-term strategy as we focus on expanding our telemedicine platform and pursuing commercialization opportunities for our CardioAI, PulmoAI, and NeuroAI artificial intelligence platforms."
The forward stock split is a strategic move to potentially increase the stock price and reduce the number of shares outstanding, which can make the stock more attractive to institutional investors and improve trading liquidity. For a development-stage company like LataMed AI, such corporate actions are often seen as a step toward building credibility and preparing for future financing or listing opportunities. The announcement comes as the company continues to develop its telehealth infrastructure and AI-enabled healthcare solutions for emerging markets, with an initial focus on Latin America.
For additional information, please visit https://latamed.ai or review the Company's filings with the U.S. Securities and Exchange Commission at www.sec.gov.
